Molecular characterization of endometrial cancer and therapeutic implications

Keyphrases

• Molecular Characterization 100%
• Endometrial Cancer 100%
• Prognostic Implications 100%
• Risk Profile 100%
• Therapeutic Implications 100%
• Adjuvant Therapy 66%
• Copy number 66%
• Polymerase 66%
• Histology 33%
• Further Development 33%
• Risk Stratification 33%
• High Risk 33%
• Endometrial Carcinoma 33%
• L1 Cell Adhesion Molecule (L1CAM) 33%
• Treatment Decisions 33%
• Molecular Alterations 33%
• Surrogate Marker 33%
• Genomic Analysis 33%
• Molecular Subtypes 33%
• Early Disease 33%
• Traditional Risk 33%
• Molecular Classification 33%
• Serous 33%
• Molecular Genomics 33%
• Endometrioid 33%
• Microsatellite Stable 33%
• Non-endometrioid 33%
• Poor Prognostic 33%
• Genomic Characterization 33%
• Microsatellite Instability-high (MSI-H) 33%

Medicine and Dentistry

• Polymerase 100%
• Uterine Cancer 100%
• Adjuvant Therapy 100%
• Malignant Neoplasm 50%
• Disease 50%
• Protein P53 50%
• Risk Stratification 50%
• Recurrent Disease 50%
• Endometrium Carcinoma 50%
• Disease Marker 50%